AR013153A1 - Derivados de 2-arildihidropirimidina, proceso para su preparacion, composiciones farmaceuticas que contienen dichos derivados, y el uso de dichosderivados y composiciones como ligandos para canales de calcio neuronales de tipo n. - Google Patents
Derivados de 2-arildihidropirimidina, proceso para su preparacion, composiciones farmaceuticas que contienen dichos derivados, y el uso de dichosderivados y composiciones como ligandos para canales de calcio neuronales de tipo n.Info
- Publication number
- AR013153A1 AR013153A1 ARP980103175A ARP980103175A AR013153A1 AR 013153 A1 AR013153 A1 AR 013153A1 AR P980103175 A ARP980103175 A AR P980103175A AR P980103175 A ARP980103175 A AR P980103175A AR 013153 A1 AR013153 A1 AR 013153A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- derivatives
- ring
- alkoxy
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados de 2-arildihidropirimidina, que comprende la formula I incluyendo su forma tautomérica 3,4-dihidropirimidina en la cual: R1 representa un anillomonocíclico aromático que optativamente incorpora una o tres heteroátomos que pueden ser iguales o diferentes y que son elegidos entre N, O o S, anillo quepuede ser optativamente sustituido con halogeno, alquilo C1 a 6, alcoxi C1 a 6 trifluorometilo; R2 represena alquilo C1 a 6 o alquilo C2 a 6, optativamenteincluyendo O, o bien S, y que está sustituido con un anillo de fenilo o heteroarilo monocíclico, anillo aromático que está sustituido con uno o mássustituyentes seleccionados entre halogeno, alquilo C1 a 6 o alcoxi C1 a 6; R3 representa un anillo monocíclico o bicíclico optativamente incorpora un átomoseleccionado entre N, O o S, optativamente sustituido con uno o más sustituyentes independientemenete seleccionados entre, alquilo C1 a 6, alcoxiC1 a 6, ciano, trifluorometilo, amino, hidroxi, nitro o carbometoxi; R4 y R5 representan independientemente hidrogeno, alquilo C1 a 6 o bencilo; o el grupoNR4R5 junto representa piperidinilo, morfolinilo, 3,4-deshidropiperidinilo, tiomorfolinilo, perhidroazepinilo, pirrolidinilo, piperazinilo o piperaziniloque también esta sustituido en N-4 por alquilo C1 a 6; R6 y R7 representan independientemente alquilo C1 a 6 o cicloalquilo C3 a 6, o bencilo,optativamente sustituido en el anillo fenilo por alquilo C1 a 6 alcoxi C1 a 6 o halogeno; X representaO, S o NR6; R8 representa hidrogeno o alquilo C1 a 6; yn representa un entero de 2 a 4; y los isomeros opticos y racematos de los mismos, así como las sales farmacéuticamente aceptables; de los mismos,procesos para su preparacion, composicionesque los contienen y su uso como antagonistas de los canales de calcio neuronales tipo N que sirven para el
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9702564A SE9702564D0 (sv) | 1997-07-02 | 1997-07-02 | New compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR013153A1 true AR013153A1 (es) | 2000-12-13 |
Family
ID=20407620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980103175A AR013153A1 (es) | 1997-07-02 | 1998-06-30 | Derivados de 2-arildihidropirimidina, proceso para su preparacion, composiciones farmaceuticas que contienen dichos derivados, y el uso de dichosderivados y composiciones como ligandos para canales de calcio neuronales de tipo n. |
Country Status (9)
Country | Link |
---|---|
US (1) | US6218538B1 (es) |
EP (1) | EP0993450A1 (es) |
JP (1) | JP2002508780A (es) |
AR (1) | AR013153A1 (es) |
AU (1) | AU8249998A (es) |
CA (1) | CA2294746A1 (es) |
SE (1) | SE9702564D0 (es) |
WO (1) | WO1999001438A1 (es) |
ZA (1) | ZA985323B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19817265A1 (de) * | 1998-04-18 | 1999-10-21 | Bayer Ag | Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe |
DE19817264A1 (de) * | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue Dihydropyrimidine |
US20040259866A1 (en) * | 1998-06-30 | 2004-12-23 | Snutch Terrance P. | Calcium channel blockers comprising two benzhydril moieties |
AU4289100A (en) * | 1999-03-25 | 2000-10-16 | Bayer Aktiengesellschaft | Dihydropyrimidines and their use in the treatment of hepatitis |
AU5568400A (en) | 1999-06-23 | 2001-01-09 | Ajinomoto Co., Inc. | Novel dihydropyrimidine derivatives |
DE10012824A1 (de) * | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
DE10012823A1 (de) * | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
DE10013126A1 (de) * | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
AU2001284504A1 (en) * | 2000-09-14 | 2002-03-26 | Ajinomoto Co., Inc. | Novel pyrimidine derivative and novel pyridine derivative |
US7314880B2 (en) * | 2003-01-02 | 2008-01-01 | Mount Cook Biosciences, Inc. | Cardioprotective delta opioid receptor agonists and methods of using same |
TW200418814A (en) * | 2003-01-02 | 2004-10-01 | Ardent Pharmaceuticals Inc | Cardioprotective delta opioid receptor agonists and methods of using same |
WO2006105670A1 (en) * | 2005-04-08 | 2006-10-12 | Neuromed Pharmaceuticals Ltd. | Combination therapy comprising an n-type calcium channel blocker for the alleviation of pain |
EP2019676A2 (en) * | 2006-05-11 | 2009-02-04 | Neuromed Pharmaceuticals, Ltd. | Method for increasing the bioavailability of benzhydryl piperazine containing compounds |
CN101225084A (zh) * | 2007-01-16 | 2008-07-23 | 北京摩力克科技有限公司 | 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
MX2013010306A (es) | 2011-03-08 | 2013-12-09 | Zalicus Pharmaceuticals Ltd | Formulaciones de dispersion solida y metodos de uso de las mismas. |
US8409560B2 (en) | 2011-03-08 | 2013-04-02 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
US20130267517A1 (en) | 2012-03-31 | 2013-10-10 | Hoffmann-La Roche Inc. | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
RU2014142598A (ru) * | 2012-03-31 | 2016-05-27 | Ф. Хоффманн-Ля Рош Аг | Новые 4-метилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в |
JP6263533B2 (ja) | 2012-08-24 | 2018-01-17 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | ジヒドロピリミジン化合物及び医薬におけるその適用 |
JP6113285B2 (ja) * | 2012-09-10 | 2017-04-12 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | B型肝炎ウイルス感染症の治療及び予防用の6−アミノ酸ヘテロアリールジヒドロピリミジン |
CA2920415A1 (en) | 2013-11-19 | 2015-05-28 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and their application in pharmaceuticals |
CN104672225B (zh) | 2013-11-27 | 2019-02-12 | 广东东阳光药业有限公司 | 二氢嘧啶衍生物的制备方法及其中间体 |
KR20160133563A (ko) | 2014-03-28 | 2016-11-22 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 다이하이드로피리미딘 화합물 및 이의 약제학적 용도 |
TW201629054A (zh) | 2015-02-07 | 2016-08-16 | 廣東東陽光藥業有限公司 | 二氫嘧啶衍生物的複合物及其在藥物中的應用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3234684A1 (de) | 1982-09-18 | 1984-03-22 | Bayer Ag, 5090 Leverkusen | Neue dihydropyrimidine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
EP0202654A3 (en) | 1985-05-20 | 1987-12-16 | E.R. Squibb & Sons, Inc. | 5-carboxy-1,4-dihydropyrimidine derivatives |
DE69500377T2 (de) | 1994-08-19 | 1997-10-09 | Mitsui Toatsu Chemicals | Pyrimidin-Dion-Derivate und diese enthaltende antiarrhythmische Zusammensetzungen |
-
1997
- 1997-07-02 SE SE9702564A patent/SE9702564D0/xx unknown
-
1998
- 1998-06-18 ZA ZA985323A patent/ZA985323B/xx unknown
- 1998-06-22 US US09/171,174 patent/US6218538B1/en not_active Expired - Fee Related
- 1998-06-22 WO PCT/SE1998/001208 patent/WO1999001438A1/en not_active Application Discontinuation
- 1998-06-22 EP EP98932675A patent/EP0993450A1/en not_active Ceased
- 1998-06-22 AU AU82499/98A patent/AU8249998A/en not_active Abandoned
- 1998-06-22 JP JP50700899A patent/JP2002508780A/ja active Pending
- 1998-06-22 CA CA002294746A patent/CA2294746A1/en not_active Abandoned
- 1998-06-30 AR ARP980103175A patent/AR013153A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
ZA985323B (en) | 1999-01-11 |
CA2294746A1 (en) | 1999-01-14 |
AU8249998A (en) | 1999-01-25 |
SE9702564D0 (sv) | 1997-07-02 |
EP0993450A1 (en) | 2000-04-19 |
US6218538B1 (en) | 2001-04-17 |
JP2002508780A (ja) | 2002-03-19 |
WO1999001438A1 (en) | 1999-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR013153A1 (es) | Derivados de 2-arildihidropirimidina, proceso para su preparacion, composiciones farmaceuticas que contienen dichos derivados, y el uso de dichosderivados y composiciones como ligandos para canales de calcio neuronales de tipo n. | |
PA8480101A1 (es) | Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos | |
AR039868A1 (es) | Inhibidores selectivos de la enzima kalikreina plasmatica | |
PA8593101A1 (es) | Composiciones para el tratamiento de crecimiento celular anormal | |
CR7698A (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
UY28514A1 (es) | Nuevos compuestos | |
UY29427A1 (es) | Derivados sustituidos de 2,3,4,5- tetrahidro-1h-pirido (4,3-b) indol, composiciones que los contienen, procesos de preparación y aplicaciones | |
CO5031253A1 (es) | Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen | |
PE20040832A1 (es) | Derivados de indolil pirazinona | |
ES2187983T3 (es) | Derivados 1,2,3,4-tetrahidronaftaleno sustituidos. | |
AR032136A1 (es) | Compuestos espiroheterociclicos utiles como inhibidores reversibles de cisteina-proteasas | |
AR025225A1 (es) | Feniloxazolidinonas heterociclicas biciclicas sustituidas antibacterianas y composiciones farmacéuticas | |
AR009938A1 (es) | Nuevos derivados de arilglicinamida, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos | |
AR013152A1 (es) | Derivados de 2-alquilheterodihidropirimidina, proceso para su preparacion, composiciones farmaceuticas que contienen dichos derivados y el uso de dichosderivados y composiciones como ligandos para canales de calcio neuronales de tipo n. | |
AR004517A1 (es) | Compuestos de imidazolin-2-4 diona sustituida, procedimiento de preparacion de dichos compuestos, y aplicacion para el uso de estos compuestos | |
UY27338A1 (es) | Nuevos derivados de ácido sulfónico | |
ECSP045420A (es) | Derivados de benzoxazina como moduladores 5-ht6 y usos de los mismos | |
UY28536A1 (es) | Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos. | |
AR044662A1 (es) | Compuestos de azetidina | |
PE20010631A1 (es) | Imidazo-3-il-aminas biciclicas, procedimiento para su preparacion y medicamentos que las contienen | |
AR016551A1 (es) | Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos | |
PA8563601A1 (es) | Acidos-3-(imidazolil)-2- alcoxipropanoicos | |
PT902684E (pt) | Derivados hexa-hidro-pirido(4,3-b)indolo utilizados como farmacos antipsicoticos | |
AR041481A1 (es) | Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar | |
DK0736012T3 (da) | Anellerede dihydropyridiner og deres anvendelse til fremstilling af farmaceutiske præparater |